Chronic myeloid leukemia (CML) is a clonal stem cell disorder characterized by the translocation t(9;22)(q34;q11) resulting in creation of the tyrosine kinase chimeric protein BCR-ABL.1 Current therapeutic management of CML patients is based on tyrosine kinase inhibitors (TKI). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.